Adjuvant therapy provides no additional recurrence-free benefit for esophageal squamous cell carcinoma patients after neoadjuvant chemoimmunotherapy and surgery: a multi-center propensity score match study

PurposeThe need for adjuvant therapy (AT) following neoadjuvant chemoimmunotherapy (nICT) and surgery in esophageal squamous cell cancer (ESCC) remains uncertain. This study aims to investigate whether AT offers additional benefits in terms of recurrence-free survival (RFS) for ESCC patients after n...

Descrición completa

Detalles Bibliográficos

Principais autores:	Shu-Han Xie, Li-Tao Yang, Hai Zhang, Zi-Lu Tang, Zhi-Wei Lin, Yi Chen, Zhi-Nuan Hong, Rong-Yu Xu, Wan-Li Lin, Ming-Qiang Kang
Formato:	Artigo
Idioma:	Inglês
Publicado:	Frontiers Media S.A. 2024-02-01
Series:	Frontiers in Immunology
Assuntos:	adjuvant therapy neoadjuvant chemoimmunotherapy esophageal cancer propensity score matching recurrence-free survival
Acceso en liña:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1332492/full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!